REG - Ondine Biomedical - Grant of Options and RSUs, and Issue of Warrants

Ondine BiomedicalAnnouncement

Mon 16:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260608:nRSH4557Ha&default-theme=true

RNS Number : 4557H  Ondine Biomedical Inc.  08 June 2026

8 June 2026

 

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

 

Grant of Options and RSUs, and Issue of Warrants

 

Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company pioneering
light-activated antimicrobial treatments, announces the issuance of Restricted
Share Units, options and warrants below.

Grant of Restricted Share Units

On 5 June 2026, the Company granted a total of 3,121,471 Restricted Share
Units ("RSUs") to employees and executive directors.

The RSUs granted to executive directors of the Company are as follows:

 Director        Position  RSUs granted  Total RSUs units now held
 Carolyn Cross   CEO       767,876       767,876
 Nicolas Loebel  CTO       716,684       716,684

 

The Restricted Share Units vest upon receipt of U.S. Food and Drug
Administration ("FDA") marketing approval for Ondine's nasal photodisinfection
therapy for the reduction of surgical site infections.

Following the grant of the RSUs, the Company has 3,121,471 RSUs to subscribe
for new common shares in the Company ("Common Shares") outstanding, which
represents c.0.56% per cent of the Company's current issued share capital.

Grant of Options

On 5 June 2026, 8,290,000 Options were granted to employees, executive
directors, non-executive directors and consultants.

The Options to the executive and non-executive directors are as follows:

 Director        Position                Options granted  Total Options now held
 Jean Charest    Non-executive Chair     400,000          740,000
 Jean Duvall     Non-executive Director  250,000          400,000
 Junaid Bajwa    Non-executive Director  250,000          400,000
 Margaret Shaw   Non-executive Director  250,000          325,000
 Carolyn Cross   Executive Director      2,000,000        4,075,000
 Nicolas Loebel  Executive Director      2,000,000        11,575,000

 

The new Options all have an exercise price of 13.25 pence, being the closing
midmarket share price on 5 June 2026 (the "Approval Date"), the day on which
the grant of Options was approved by the Board. The Options vest evenly over a
period of three years, with 33.33% vesting on each of the three successive
anniversaries of the Approval Date and can be exercised for a period of eight
years from the Approval Date.

Following the grant of the new Options, the Company has 26,528,334 Options to
subscribe for new Common Shares outstanding, which represents c.4.73% per cent
of the Company's current issued share capital.

Issue of Warrants

On 5 June 2026, the Company issued 1,000,000 warrants to an executive,
entitling the holder to acquire Common Shares of the Company at a strike price
of 15 pence each. The warrants have an expiration date of six months following
receipt of U.S. Food and Drug Administration ("FDA") marketing approval for
Ondine's nasal photodisinfection therapy for the reduction of surgical site
infections.

Following the grant of the warrants, the Company has 1,000,000 warrants to
subscribe for new Common Shares outstanding, which represents c.0.18% per cent
of the Company's current issued share capital.

 
Enquiries:
 Ondine Biomedical Inc.                                ondinebio.com
 Carolyn Cross, CEO                                    +1 604 669 0555

 Strand Hanson Limited (Nominated & Joint Financial Adviser)
 James Harris, Richard Johnson, Imogen Ellis           +44 (0)20 7409 3494

 Peel Hunt LLP (Broker & Joint Financial Adviser)
 James Steel, Dr. Chris Golden                         +44 (0)20 7418 8900

 5654 & Company (Financial PR and IR Adviser)          ondinebiomedical@5654.co.uk
 Matthew Neal, Chris Gardner, Melissa Gardiner         +44 0791 7800 011

                                                       +44 0775 7697 357

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company focused on the
development of light-activated antimicrobial therapies ('photodisinfection')
for the prevention and treatment of infections, including those associated
with multidrug-resistant organisms.

Ondine's lead product, Steriwave(®), is authorized for nasal decolonisation
in Canada and certain international markets. In the United States, the
technology has been granted Qualified Infectious Disease Product designation
and Fast Track status by the U.S. Food and Drug Administration and recently
completed enrolment in its Phase 3 clinical trial.

The Company has a pipeline of additional photodisinfection products in various
stages of development for application in areas including chronic sinusitis,
ventilator-associated pneumonia, burns and other indications.

U.S. Regulatory Status and Clinical Data Disclaimer

Ondine's light-activated antimicrobial technology, commercially available as
Steriwave(®) in certain jurisdictions, is not approved, cleared, or
commercially available for sale or clinical use in the United States and is
limited by U.S. law to investigational use only.

References to clinical outcomes in this release should be interpreted in the
context of the specific studies or real-world evaluations described and do not
imply regulatory approval for any particular indication.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEVLFBQQLFBBE



            Copyright 2019 Regulatory News Service, all rights reserved